ES2548127T3 - Activadores y aplicaciones terapéuticas de los mismos - Google Patents
Activadores y aplicaciones terapéuticas de los mismos Download PDFInfo
- Publication number
- ES2548127T3 ES2548127T3 ES08775506.2T ES08775506T ES2548127T3 ES 2548127 T3 ES2548127 T3 ES 2548127T3 ES 08775506 T ES08775506 T ES 08775506T ES 2548127 T3 ES2548127 T3 ES 2548127T3
- Authority
- ES
- Spain
- Prior art keywords
- compounds
- activators
- therapeutic applications
- cell
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 230000001225 therapeutic effect Effects 0.000 title description 3
- 239000012190 activator Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract description 14
- 150000003839 salts Chemical class 0.000 abstract description 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- ZNPSDSMZKLWRLO-UHFFFAOYSA-N 2,4,7,9-tetramethylbenzo[b][1,8]naphthyridin-5-amine Chemical compound N1=C(C)C=C(C)C2=C(N)C3=CC(C)=CC(C)=C3N=C21 ZNPSDSMZKLWRLO-UHFFFAOYSA-N 0.000 description 1
- WRUVTYDQVPMYDZ-UHFFFAOYSA-N 2,4,9-trimethylbenzo[b][1,8]naphthyridin-5-amine Chemical compound C1=CC=C(C)C2=NC3=NC(C)=CC(C)=C3C(N)=C21 WRUVTYDQVPMYDZ-UHFFFAOYSA-N 0.000 description 1
- 125000005809 3,4,5-trimethoxyphenyl group Chemical group [H]C1=C(OC([H])([H])[H])C(OC([H])([H])[H])=C(OC([H])([H])[H])C([H])=C1* 0.000 description 1
- -1 4-ethoxyphenyl Chemical group 0.000 description 1
- 208000003950 B-cell lymphoma Diseases 0.000 description 1
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 1
- 101000721661 Homo sapiens Cellular tumor antigen p53 Proteins 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- OPFJDXRVMFKJJO-ZHHKINOHSA-N N-{[3-(2-benzamido-4-methyl-1,3-thiazol-5-yl)-pyrazol-5-yl]carbonyl}-G-dR-G-dD-dD-dD-NH2 Chemical compound S1C(C=2NN=C(C=2)C(=O)NCC(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(N)=O)=C(C)N=C1NC(=O)C1=CC=CC=C1 OPFJDXRVMFKJJO-ZHHKINOHSA-N 0.000 description 1
- 208000002151 Pleural effusion Diseases 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 230000002622 anti-tumorigenesis Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 230000027455 binding Effects 0.000 description 1
- 230000029918 bioluminescence Effects 0.000 description 1
- 238000005415 bioluminescence Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229940126086 compound 21 Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- DRDAFDJAYXZMJW-UHFFFAOYSA-N ethyl 4-[3-(dimethylamino)propylamino]-6,8-dimethylquinoline-3-carboxylate Chemical compound CC1=CC(C)=CC2=C(NCCCN(C)C)C(C(=O)OCC)=CN=C21 DRDAFDJAYXZMJW-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000004565 tumor cell growth Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
- C07D215/46—Nitrogen atoms attached in position 4 with hydrocarbon radicals, substituted by nitrogen atoms, attached to said nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Una composición farmacéutica que comprende un compuesto que tiene la fórmula**Fórmula** o la fórmula**Fórmula** o una sal farmacéuticamente aceptable del mismo; y un vehículo farmacéuticamente aceptable.
Description
E08775506
23-09-2015
- Identificación del compuesto
- Estructura Nombre (IUPAC) Fórmula
- 7
- C20H21N5O
- 9
- 4-(3-dimetilaminopropilamino)-6,8dimetil-quinolina-3-carboxilato de etilo C19H27N3O2
- 15
- C20H23N5OS
- 20
- 5-(4-etoxifenil)-7-(3,4,5-trimetoxifenil)4,7-dihidro-[1,2,4]triazolo[1,5α]pirimidina
- 21
- C21H20N4O2
- 22
- 2,4,7,9-tetrametilbenzo[b]-1,8-naftiridin5-amina C16H17N3
- 23
- 2,4,9-trimetilbenzo[b]-1,8-naftiridin-5amina C15H15N3
Se reivindican los compuestos 7 y 21 y su uso en el tratamiento del cáncer. Los compuestos 1, 9, 15, 20, 22 y 23 son compuestos de referencia.
Además de los compuestos 7 y 21, también se incluyen en la invención los homólogos cercanos e isómeros
5 posicionales de los compuestos que tienen aplicabilidad terapéutica igual o más potente. Los homólogos cercanos son compuestos que difieren, por ejemplo, por la sustitución de un resto químico en el compuesto con un resto químico sucesivo, por ejemplo, la sustitución con un grupo metilo o un grupo etilo o viceversa. También se incluyen en la invención las sales farmacéuticamente aceptables, ésteres y profármacos de los compuestos.
La cantidad de molécula pequeña de la invención utilizada para aplicaciones terapéuticas varía con las 10 consideraciones estándar, tales como la naturaleza de la afección que se trata, y la edad y condición del paciente, y
5
E08775506
23-09-2015
en el ratón utilizando inyecciones intraperitoneales de los compuestos 7, 9, 15, 21, y 22 (9 dosis/3 semanas) no mostraron ninguna toxicidad aparente en los animales como se indica mediante las curvas de peso (Figura 7), patologías macroscópicas, o tinción de hematoxilina-eosina de tejidos tales como el timo, bazo, intestino, hígado o riñón (no mostrados). Soporte para su utilidad potencial como agentes anti-tumorales se indica mediante un modelo de linfoma de células B ortotópico. Los ratones fueron inyectados con células de linfoma de derrame pleural BC-3 establemente integradas con un gen reportero de luciferasa (Keller et al., 2006). Una vez que se establecieron los tumores, según lo medido por el monitor de bioluminiscencia in vivo, los ratones se trataron con inyecciones intraperitoneales de los compuestos tres veces a la semana. El tratamiento de los animales con los compuestos 15 y 22 condujo a la inhibición visible del crecimiento de células tumorales mientras que el compuesto 21 no tuvo ningún efecto (Figura 8). Los resultados indican potenciales efectos anti-tumorigénicos de los compuestos.
Referencias
Cho Y, Gorina S, Jeffrey PD, la estructura Pavletich N P. Crystal structure of a p53 tumor suppresor DNA complex, understanding tumorigenic mutations. Science 1994 265: 346-55.
el-Deiry WS, Kern SE, Pietenpol JA, Kinzler KW, Vogelstein B. Definition of a consensus binding site for p53. Nat. Genet. 1992 1: 45-9.
Friedman PN, Chen X, Bargonetti J, Prives C. The p53 protein is an unusually shaped tetramer that binds directly to DNA. Proc Natl Acad Sci EE.UU. 1,993 90: 3319-23.
Haapajarvi T, Pitkanen K, Laiho M. Human melanoma cell line UV responses show independecy of p53 function. Cell Growth Differ 1,999 10: 163 a 71.
Keller S A, Hernandez-Hopkins D, Vider J, Ponomarev V, Hyjek E, Schattner E J, Cesarman E. NF-kappaB is essential for the progression of KSHV-and EBV-infected lymphomas in vivo. Blood. 2006 107:3295-302.
Kern S E, Kinzler K W, Bruskin A, Jarosz D, Friedman P, Prives C, Vogelstein B. Identification of p53 as a sequencespecific DNA-binding protein. Science. 1991 252:1708-11.
Kim E, Albrechtsen N, Deppert W. DNA-conformation is an important determinant of sequence-specific DNA binding by tumor suppressor p53. Oncogene. 1997 15:857-69.
Levrero M, De Laurenzi V, Costanzo A, Gong J, Wang J Y, Melino G. The p53/p63/p73 family of transcription factors: overlapping and distinct functions. J Cell Sci. 2000 113:1661-70.
Martins C P, Brown-Swigart L, Evan G1. Modeling the therapeutic efficacy of p53 restoration in tumors. Cell 2006 127:1323-34.
Melino G, Lu X, Gasco M, Crook T, Knight R A. Functional regulation of p73 and p63: development and cancer. Trends Biochem Sci. 2003 28:663-70.
Murray-Zmijewski F, Lane D P, Bourdon J C. p53/p63/p73 isoforms: an orchestra of isoforms to harmonise cell differentiation and response to stress. Cell Death Differ. 2006 13:962-72.
Sarek G, Kurki S, Enback J, Iotzova G, Haas J, Laakkonen P, Laiho M, Ojala P M. Reactivation of the p53 pathway as a treatment modality for KSHV-induced lymphomas. J Clin Invest. 2007 117:1019-28.
Vassilev L T, Vu B T, Graves B, Carvajal D, Podlaski F, Filipovic Z, Kong N, Kammlott U, Lukacs C, Klein C, Fotouhi N, Liu E A. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science. 2004 303:844-8.
Ventura A, Kirsch D G, McLaughlin M E, Tuveson D A, Grimm J, Lintault L, Newman J, Reczek E E, Weissleder R, Jacks T. Restoration of p53 function leads to tumour regression in vivo. Nature 2007 445:661-5.
Vousden K H, Lane D P. p53 in health and disease. Nat Rev Mol Cell Biol. 2007 8:275-83.
Wang L, Wu Q, Qiu P, Mirza A, McGuirk M, Kirschmeier P, Greene J R, Wang Y, Pickett C B, Liu S. Analyses of p53 target genes in the human genome by bioinformatic and microarray approaches. J Biol. Chem. 2001 276:43604-10.
Wei C L, Wu Q, Vega V B, Chiu K P, Ng P, Zhang T, Shahab A, Yong H C, Fu Y, Weng Z, Liu J, Zhao X D, Chew J L, Lee Y L, Kuznetsov V A, Sung W K, Miller L D, Lim B, Liu E T, Yu Q, Ng H H, Ruan Y. A global map of p53 transcription-factor binding sites in the human genome. Cell. 2006 124:207-19.
Xing J, Sheppard H M, Corneillie S I, Liu X. p53 Stimulates TFIID-TFIIA-promoter complex assembly, and p53-T antigen complex inhibits TATA binding protein-TATA interaction. Mol Cell Biol. 2001 21:3652-61.
10
Claims (1)
-
imagen1 imagen2
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/FI2007/000175 WO2008155441A1 (en) | 2007-06-20 | 2007-06-20 | Activators and therapeutic applications thereof |
| WOPCT/FI2007/000175 | 2007-06-20 | ||
| PCT/FI2008/050381 WO2008155468A1 (en) | 2007-06-20 | 2008-06-19 | Activators and therapeutic applications thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2548127T3 true ES2548127T3 (es) | 2015-10-14 |
Family
ID=40155942
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES08775506.2T Active ES2548127T3 (es) | 2007-06-20 | 2008-06-19 | Activadores y aplicaciones terapéuticas de los mismos |
| ES14197817T Active ES2699735T3 (es) | 2007-06-20 | 2008-06-19 | Activadores y aplicaciones terapéuticas de los mismos |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES14197817T Active ES2699735T3 (es) | 2007-06-20 | 2008-06-19 | Activadores y aplicaciones terapéuticas de los mismos |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US8680107B2 (es) |
| EP (3) | EP2889297B1 (es) |
| CA (2) | CA2912456C (es) |
| ES (2) | ES2548127T3 (es) |
| WO (2) | WO2008155441A1 (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3778600A1 (en) * | 2014-03-20 | 2021-02-17 | The Johns Hopkins University | Compounds which inhibit rna polymerase, compositions including such compounds, and their use |
| US10111876B2 (en) * | 2016-08-17 | 2018-10-30 | Macau University Of Science And Technology | ALK Kinase Inhibitor and its use |
| CA3037928A1 (en) * | 2016-09-23 | 2018-03-29 | The Johns Hopkins University | Combinatory treatment strategies of cancer based on rna polymerase i inhibition |
| CN110128477B (zh) * | 2018-02-09 | 2021-08-27 | 天津医科大学 | 基于核仁应激的铂类化合物 |
| CN110305128B (zh) * | 2019-07-31 | 2021-08-24 | 桂林医学院 | 5-氨基苯并[b][1,8]萘啶类化合物的制备方法和应用 |
| WO2022060816A1 (en) * | 2020-09-15 | 2022-03-24 | The Johns Hopkins University | Compounds which inhibit rna polymerase |
| WO2022093919A1 (en) * | 2020-10-28 | 2022-05-05 | Dana-Farber Cancer Institute, Inc. | Inhibitors of exo1 in combination with other cancer drugs to inhibit cancer cells |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5908840A (en) * | 1996-11-26 | 1999-06-01 | American Cyanamid Company | Hetero-biaryl-pyridoquinazolinone derivatives as anti-cancer agents |
| HUP0201215A2 (en) | 1998-12-02 | 2002-08-28 | Pfizer Prod Inc | Methods and compositions for restoring conformational stability of a protein of the p53 family |
| WO2002014321A1 (en) * | 2000-08-11 | 2002-02-21 | The Regents Of The University Of California | Use of stat-6 inhibitors as therapeutic agents |
| US7132421B2 (en) * | 2003-06-17 | 2006-11-07 | Hoffmann-La Roche Inc. | CIS-imidazoles |
| MXPA05013922A (es) * | 2003-06-20 | 2006-02-24 | Coley Pharm Group Inc | Antagonistas de receptor tipo toll de molecula pequena. |
| WO2006093518A2 (en) * | 2004-06-25 | 2006-09-08 | Apath, Llc | Thienyl compounds for treating virus-related conditions |
| US20090221624A1 (en) * | 2005-05-06 | 2009-09-03 | Olivo Paul D | 4-aminoquinoline compounds for treating virus-related conditions |
| CA2644643C (en) * | 2006-03-22 | 2015-05-19 | Janssen Pharmaceutica N.V. | Inhibitors of the interaction between mdm2 and p53 |
-
2007
- 2007-06-20 WO PCT/FI2007/000175 patent/WO2008155441A1/en not_active Ceased
-
2008
- 2008-06-19 EP EP14197817.1A patent/EP2889297B1/en active Active
- 2008-06-19 CA CA2912456A patent/CA2912456C/en active Active
- 2008-06-19 CA CA2691227A patent/CA2691227C/en active Active
- 2008-06-19 US US12/665,473 patent/US8680107B2/en active Active
- 2008-06-19 ES ES08775506.2T patent/ES2548127T3/es active Active
- 2008-06-19 EP EP08775506.2A patent/EP2195316B1/en active Active
- 2008-06-19 WO PCT/FI2008/050381 patent/WO2008155468A1/en not_active Ceased
- 2008-06-19 EP EP18192915.9A patent/EP3427736B1/en active Active
- 2008-06-19 ES ES14197817T patent/ES2699735T3/es active Active
-
2014
- 2014-02-04 US US14/171,845 patent/US10214491B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP2195316A1 (en) | 2010-06-16 |
| CA2691227C (en) | 2016-02-02 |
| EP3427736A1 (en) | 2019-01-16 |
| EP2889297A3 (en) | 2015-09-23 |
| CA2691227A1 (en) | 2008-12-24 |
| US8680107B2 (en) | 2014-03-25 |
| CA2912456C (en) | 2018-08-21 |
| EP2195316A4 (en) | 2012-02-01 |
| CA2912456A1 (en) | 2008-12-24 |
| US20100179155A1 (en) | 2010-07-15 |
| EP2195316B1 (en) | 2015-08-12 |
| US10214491B2 (en) | 2019-02-26 |
| WO2008155441A1 (en) | 2008-12-24 |
| US20140155432A1 (en) | 2014-06-05 |
| EP3427736B1 (en) | 2024-06-19 |
| ES2699735T3 (es) | 2019-02-12 |
| EP2889297A2 (en) | 2015-07-01 |
| EP2889297B1 (en) | 2018-10-03 |
| WO2008155468A1 (en) | 2008-12-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2548127T3 (es) | Activadores y aplicaciones terapéuticas de los mismos | |
| ES2528376T3 (es) | Forma cristalina de un inhibidor de la interacción de MDM2/4 y p53 | |
| ES2536313T3 (es) | Imidazo[4,5-c]quinolinas como inhibidores de ADN-PK | |
| ES2773480T3 (es) | Composiciones y métodos para tratar la enfermedad de Alzheimer | |
| JP6027230B2 (ja) | ５−［［４−［［モルホリン−２−イル］メチルアミノ］−５−（トリフルオロメチル）−２−ピリジル］アミノ］ピラジン−２−カルボニトリルおよびその治療上の使用 | |
| ES2532732T3 (es) | Uso de un inhibidor de CDK para el tratamiento del glioma | |
| ES2602465T3 (es) | Combinaciones para el tratamiento de enfermedades que implican una proliferación celular | |
| JP5992054B2 (ja) | ピラゾロピロリジン化合物 | |
| JP2015506376A (ja) | Ｃｄｋ８／ｃｄｋ１９選択的阻害剤、ならびに癌のための抗転移および化学防御の方法におけるそれらの使用 | |
| ES2828984T3 (es) | Derivados de 2-((5-(1-(3-(metilsulfonil)propil)piperidin-4-il)piridin-2-il)amino)pirido[2,3-D]pirimidin-7(8H)-ona y compuestos relacionados como inhibidores de CDK4 para tratar tumores | |
| WO2012016133A2 (en) | Ros1 kinase inhibitors for the treatment of glioblastoma and other p53-deficient cancers | |
| US20160002222A1 (en) | Prodrug forms of kinase inhibitors and their use in therapy | |
| JP2021088580A (ja) | Ｅｇｆｒ及びｐｉ３ｋの小分子阻害剤 | |
| EP2598508B1 (en) | Isoxazolo-quinazolines as modulators of protein kinase activity | |
| AU2020241703A1 (en) | Compositions and methods for treating cancer | |
| PT2663564E (pt) | Composto de imidazo[4,5-c]quinolin-2-ona e a sua utilização como inibidor dual de quinase pi3/mtor | |
| ES2953005T3 (es) | Tratamiento para el cáncer | |
| JP2022504541A (ja) | 低分子ｍｄｍ２タンパク質デグレーダー | |
| ES2562820T3 (es) | Derivados de indirubin-3'-oxima como potentes inhibidores de la cinasa dependientes de ciclina | |
| JP2015503507A5 (es) | ||
| RU2014152790A (ru) | Пирролопиразоновые ингибиторы танкиразы | |
| ES2968421T3 (es) | Atropisomerismo para la selectividad potenciada de inhibidor de cinasa | |
| TW200843766A (en) | Treatment of melanoma | |
| RU2016110874A (ru) | Комбинация ингибитора alk и ингибитора cdk для лечения клеточных пролиферативных заболеваний | |
| EP3630099A1 (en) | Bax activators and uses thereof in cancer therapy |